Gainers

• InflaRx (NASDAQ:IFRX) stock rose 12.7% to $1.32 during Friday's after-market session. The market value of their outstanding shares is at $182.6 million.
• Instinct Bio Technical Co (NASDAQ:BIOT) stock moved upwards by 5.83% to $0.2. The market value of their outstanding shares is at $5.4 million.
• Can Fite Biopharma (AMEX:CANF) stock moved upwards by 4.34% to $1.48. The company's market cap stands at $3.1 million.
• NextCure (NASDAQ:NXTC) stock moved upwards by 3.43% to $6.62. The market value of their outstanding shares is at $28.5 million. The company's, Q3 earnings came out 3 days ago.
• Modular Medical (NASDAQ:MODD) stock rose 3.37% to $2.04. The market value of their outstanding shares is at $13.7 million.
• Marker Therapeutics (NASDAQ:MRKR) shares increased by 2.88% to $0.9. The market value of their outstanding shares is at $15.0 million.

Losers

• VolitionRX (AMEX:VNRX) shares declined by 6.3% to $0.22 during Friday's after-market session. The company's market cap stands at $5.5 million. The company's, Q3 earnings came out yesterday.
• Xtant Medical Holdings (AMEX:XTNT) stock fell 5.34% to $0.27. The company's market cap stands at $38.6 million.
• Akanda (NASDAQ:AKAN) shares declined by 5.0% to $1.3. The company's market cap stands at $1.7 million.
• XORTX Therapeutics (NASDAQ:XRTX) shares decreased by 3.64% to $1.06. The company's market cap stands at $1.6 million.
• NewGenIvf Group (NASDAQ:NIVF) stock fell 3.42% to $0.22.
• Nautilus Biotechnology (NASDAQ:NAUT) stock fell 3.41% to $2.24. The company's market cap stands at $303.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.